Matthew McIlwain - Jun 14, 2024 Form 4 Insider Report for Nautilus Biotechnology, Inc. (NAUT)

Role
Director
Signature
/s/ Mathew B. Murphy, as Attorney-in-Fact
Stock symbol
NAUT
Transactions as of
Jun 14, 2024
Transactions value $
$0
Form type
4
Date filed
6/17/2024, 06:09 PM
Previous filing
Dec 14, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NAUT Stock Option (Right to Buy) Award $0 +45K $0.00 45K Jun 14, 2024 Common Stock 45K $2.56 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Subject to reporting person's continuous status as a "Service Provider" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).